Hyoscyamine Sulfate Drops Rx
Generic Name and Formulations:
Hyoscyamine sulfate 0.125mg/mL; alcohol 5%; orange flavor.
Various generic manufacturers
Indications for Hyoscyamine Sulfate Drops:
Adjunct in peptic ulcer. Irritable bowel syndrome. Infant colic.
1–2mL every 4 hrs or as needed; max 12mL/day.
3.4kg: 4 drops. 5kg: 5 drops. 7kg: 6 drops. 10kg: 8 drops. Older children (2 yrs–12 yrs): 0.25–1mL; max 6mL/day. All: every 4 hrs or as needed.
Glaucoma. Unstable cardiovascular status in acute hemorrhage. GI or urinary tract obstruction. Paralytic ileus, intestinal atony of elderly or debilitated patients. Toxic megacolon. Severe ulcerative colitis. Myasthenia gravis.
High environmental temperature. Diarrhea. Autonomic neuropathy. Impaired cardiac or renal function. Cardiovascular disease. Hypertension. Hyperthyroidism. Hiatal hernia with reflux esophagitis. Pregnancy (Cat.C). Nursing mothers.
Antacids may inhibit absorption. Additive anticholinergic effects with other anticholinergics, amantadine, type I antiarrhythmics, antihistamines, phenothiazines, tricyclics, MAOIs.
Anticholinergic effects, drowsiness.
Formerly known under the brand name Levsin Drops.
Tabs, SL—100, 500; Drops—contact supplier
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies